OMEROS CORP (OMER)
US6821431029 - Common Stock
We assign a fundamental rating of 1 out of 10 to OMER. OMER was compared to 193 industry peers in the Pharmaceuticals industry. OMER may be in some trouble as it scores bad on both profitability and health. OMER is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year OMER has reported negative net income.
In the past year OMER has reported a negative cash flow from operations.
In multiple years OMER reported negative net income over the last 5 years.
In the past 5 years OMER reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -42.93%, OMER is in line with its industry, outperforming 43.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.93% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OMER so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, OMER has less shares outstanding
Compared to 5 years ago, OMER has more shares outstanding
The debt/assets ratio for OMER is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.57, we must say that OMER is in the distress zone and has some risk of bankruptcy.
OMER's Altman-Z score of -4.57 is on the low side compared to the rest of the industry. OMER is outperformed by 62.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.57 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.96 indicates that OMER has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.96, OMER is in line with its industry, outperforming 50.26% of the companies in the same industry.
OMER has a Quick Ratio of 2.96. This indicates that OMER is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.96, OMER is in line with its industry, outperforming 54.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
OMER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -821.88%.
EPS 1Y (TTM)-821.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, OMER will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.43% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-57.88%
EPS Next 2Y-8%
EPS Next 3Y1.83%
EPS Next 5Y15.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8%
EPS Next 3Y1.83%
5. Dividend
5.1 Amount
No dividends for OMER!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OMEROS CORP
NASDAQ:OMER (12/20/2024, 5:06:24 PM)
After market: 10.21 -0.1 (-0.97%)10.31
+0.07 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.49%
Inst Owner Change3.12%
Ins Owners4.56%
Ins Owner Change0%
Market Cap597.46M
Analysts80
Price Target43.86 (325.41%)
Short Float %16.11%
Short Ratio9.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.15%
Min EPS beat(2)16.34%
Max EPS beat(2)21.96%
EPS beat(4)3
Avg EPS beat(4)26.36%
Min EPS beat(4)-6.37%
Max EPS beat(4)73.5%
EPS beat(8)6
Avg EPS beat(8)71.14%
EPS beat(12)9
Avg EPS beat(12)55.89%
EPS beat(16)13
Avg EPS beat(16)46.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-40.74%
EPS NQ rev (3m)-40.74%
EPS NY rev (1m)3.55%
EPS NY rev (3m)3.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.31
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-2.67
OCFYN/A
SpS0
BVpS-2.66
TBVpS-2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.93% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.09% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | -4.57 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.05%
Cap/Depr(5y)22.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-821.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y-57.88%
EPS Next 2Y-8%
EPS Next 3Y1.83%
EPS Next 5Y15.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.98%
OCF growth 3YN/A
OCF growth 5YN/A